126 related articles for article (PubMed ID: 23019306)
21. T-cell therapy targets glioblastoma.
Cancer Discov; 2015 May; 5(5):458. PubMed ID: 25783861
[No Abstract] [Full Text] [Related]
22. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
24. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
25. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies.
Jarboe JS; Johnson KR; Choi Y; Lonser RR; Park JK
Cancer Res; 2007 Sep; 67(17):7983-6. PubMed ID: 17804706
[TBL] [Abstract][Full Text] [Related]
26. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.
Samaha H; El Naggar S; Ahmed N
Immunotherapy; 2015; 7(5):481-5. PubMed ID: 26065474
[No Abstract] [Full Text] [Related]
27. A novel target anti-interleukin-13 receptor subunit alpha-2 monoclonal antibody inhibits tumor growth and metastasis in lung cancer.
Raza G; Yunus FU; Mangukiya HB; Merugu SB; Mashausi DS; Zeling W; Negi H; Zhou B; Roy D; Wu Z; Li D
Int Immunopharmacol; 2021 Jan; 90():107155. PubMed ID: 33243603
[TBL] [Abstract][Full Text] [Related]
28. Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells.
Yan X; Su Z; Zhang J; Wu Z; Ye S; Lu X; Wu J; Zeng Y; Zheng W
Cell Immunol; 2010; 263(2):172-5. PubMed ID: 20400066
[TBL] [Abstract][Full Text] [Related]
29. Immuno-informatics analysis and expression of a novel multi-domain antigen as a vaccine candidate against glioblastoma.
Gharbavi M; Danafar H; Amani J; Sharafi A
Int Immunopharmacol; 2021 Feb; 91():107265. PubMed ID: 33360829
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives.
Karschnia P; Teske N; Thon N; Subklewe M; Tonn JC; Dietrich J; von Baumgarten L
Neurology; 2021 Aug; 97(5):218-230. PubMed ID: 33986138
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
Choi BD; Maus MV; June CH; Sampson JH
Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
[TBL] [Abstract][Full Text] [Related]
32. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.
Firor AE; Jares A; Ma Y
Exp Biol Med (Maywood); 2015 Aug; 240(8):1087-98. PubMed ID: 25956686
[TBL] [Abstract][Full Text] [Related]
33. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
[TBL] [Abstract][Full Text] [Related]
34. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
35. Generation of regulable EGFRvIII targeted chimeric antigen receptor T cells for adoptive cell therapy of glioblastoma.
Zheng Y; Gao N; Fu YL; Zhang BY; Li XL; Gupta P; Wong AJ; Li TF; Han SY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):59-66. PubMed ID: 30409424
[TBL] [Abstract][Full Text] [Related]
36. Interleukin 13 receptor alpha 2 (IL13Rα2): Expression, signaling pathways and therapeutic applications in cancer.
Jaén M; Martín-Regalado Á; Bartolomé RA; Robles J; Casal JI
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188802. PubMed ID: 36152905
[TBL] [Abstract][Full Text] [Related]
37. Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Chen N; Li X; Chintala NK; Tano ZE; Adusumilli PS
Curr Opin Immunol; 2018 Apr; 51():103-110. PubMed ID: 29554494
[TBL] [Abstract][Full Text] [Related]
38. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T cell treatment in hematologic malignancies.
Goker H; Malkan UY; Demiroglu H; Buyukasik Y
Transfus Apher Sci; 2016 Feb; 54(1):35-40. PubMed ID: 26874466
[TBL] [Abstract][Full Text] [Related]
40. Optimization of T Cell Redirecting Strategies: Obtaining Inspirations From Natural Process of T Cell Activation.
Gao Y; Wang Y; Luo F; Chu Y
Front Immunol; 2021; 12():664329. PubMed ID: 33981310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
